YUMAB GmbH

Booth number 4517-04

www.yumab.com

YUMAB develops therapeutic antibodies for clients and partners using one of world’s largest human antibody libraries (>10e11), patient derived libraries or immune libraries.

About us

YUMAB develops therapeutic antibodies for clients and partners using one of world’s largest human antibody libraries (>10e11), patient derived libraries or immune libraries.

YUMAB's integrated discovery and engineering platform offers highest success-rates to all types of antigens including “difficult” targets such as GPCRs, transporters or ion channels.

YUMAB provides all technologies from target to optimized lead in one hand. Technologies include fast track in vitro antibody selection and screening (including on cell selection), antibody engineering (including superhumanization) and bioinformatic lead optimization.

Newest achievement is the fast track COVID-19 program of YUMAB's spin-off CORAT Therapeutics from target to patient in 11 months.

Address
YUMAB GmbH
Inhoffenstr. 7
38124 Braunschweig
Germany

Phone: +49 531 4811700
Internet: www.yumab.com

Contact person

Alexander Ehm
Head of Business Development & Marketing
Phone: +49 1702 800357
Representative
YUMAB Inc.
1100 South Tower 225, Peachtree Str.
30303 Atlanta GA
U.S.A.

Internet: www.yumab.com

Products and Services

  • Antibody Libraries

  • Antibody Discovery

  • Antibody Development

  • Antibody Engineering

  • Antibody Humanization
YUMAB® Antibody libraries

YUMAB® Antibody Library Features
- Natural antibody repertoires (no synthetic sequences)
- Universal and broad repertoire (all human frame works and CDR lengths)
- Large epitope coverage and high hit rate
- Flexible business conditions

Further reading

YUMAB® Antibody discovery

YUMAB® Antibody discovery technologies.
- The power of in-vitro antibody selection.
- Challenging difficult targets by optimized discovery solutions.
- From target to lead.

Further reading

YUMAB® humanization platform

YUMAB® humanization platform:
- Germline-optimized CDR grafting
- Template-driven chain shuffling

Further reading

News & Innovations

Discovery of a neutralizing antibody to treat Covid-19

Fast track development of SARS-CoV-2 antibody (6 months).

In less than six months, an antibody gene library was generated, screened against SARS-CoV-2 S1 protein and a fi nal lead molecule (COR-101) was identifi ed by a set of selected assays including life virus neutralization and CMC assessment YUMAB‘s antibody discovery and development platform identifi ed several promising candidates with high affi nity, very good developability prediction and binding to most presently known SARS-CoV-2 variants.

Antibodies expressed at GMP standards after stable cell line development show a high expression titer and exhibit good developability.

Click here if you notice an image that violates copyright or privacy rights.

Get in contact
OK

We only use functionally necessary cookies and the web analysis tool Matomo in order to optimally design and continuously improve our website for you. By continuing to use our website, you agree to this. Further information and an objection possibility can be found here: Data protection